- Home
- IBRX vs PRIM Comparison
IBRX vs PRIM Comparison
Compare IBRX & PRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | PRIM |
|---|---|---|
| Founded | 2014 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.1B |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | IBRX | PRIM |
|---|---|---|
| Price | $7.27 | $122.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | $12.57 | ★ $155.20 |
| AVG Volume (30 Days) | ★ 13.3M | 2.7M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.19% |
| EPS Growth | 38.71 | ★ 51.66 |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $9.92 |
| Revenue Next Year | $131.15 | $8.80 |
| P/E Ratio | ★ N/A | $394.43 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $70.68 |
| 52 Week High | $12.43 | $205.50 |
Technical Indicators
Market Signals| Indicator | IBRX | PRIM |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 45.08 |
| Support Level | $6.64 | $111.88 |
| Resistance Level | $8.54 | $127.97 |
| Average True Range (ATR) | 0.54 | 6.61 |
| MACD | -0.07 | 2.31 |
| Stochastic Oscillator | 9.16 | 59.21 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About PRIM Primoris Services Corporation
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.